adenocarcinoma (PDAC) is challenging to treat, and better means to detect and/or treat 25 pancreatic cancer are urgently needed to save lives. Cathepsin E (Cath E) is a proteolytic enzyme highly 26 expressed in PDAC. In this study, a novel approach using Cath E activation of a Cath E-specific prodrug was 27 demonstrated. Specific activation of the prodrug is expected to kill pancreatic cancer cells without harming 28 normal pancreatic cells. A novel 5-aminolevulinic acid (5-ALA) prodrug was custom-designed to be activated 29 selectively by endogenous Cath E within the PDAC cells. The 5-ALA prodrug was incubated with Cath 30 E-positive and -negative tumor cells and illuminated with various doses of light. In addition, mice genetically 31 engineered to develop PDAC were injected intravenously with the 5-ALA prodrug, and the pancreas was 32 treated with light irradiation. One day after treatment, PDAC tissue was assessed for apoptosis. The 5-ALA 33 prodrug was activated within the Cath E-positive tumor but not in the normal pancreatic tissue. When 34 used in combination with light treatment, it allowed delivery of selective photodynamic therapy (PDT) to 35 the cancerous tissues, with minimal harm to the adjacent normal tissues. With this novel Cath E activation 36 approach, it is possible to detect pancreatic cancer cells accurately and specifically impair their viability, 37 while sparing normal cells. This treatment could result in fewer side effects than the non-specific treatments 38 currently in use. Cath E is a specific and effective drug activator for PDAC treatment.
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Pancreatic ductal adenocarcinoma (PDAC) is challenging to treat, and better means to detect and/or treat 25 pancreatic cancer are urgently needed to save lives. Cathepsin E (Cath E) is a proteolytic enzyme highly 26 expressed in PDAC. In this study, a novel approach using Cath E activation of a Cath E-specific prodrug was 27 demonstrated. Specific activation of the prodrug is expected to kill pancreatic cancer cells without harming 28 normal pancreatic cells. A novel 5-aminolevulinic acid (5-ALA) prodrug was custom-designed to be activated 29 selectively by endogenous Cath E within the PDAC cells. The 5-ALA prodrug was incubated with Cath 30 E-positive and -negative tumor cells and illuminated with various doses of light. In addition, mice genetically 31 engineered to develop PDAC were injected intravenously with the 5-ALA prodrug, and the pancreas was 32 treated with light irradiation. One day after treatment, PDAC tissue was assessed for apoptosis. The 5-ALA 33 prodrug was activated within the Cath E-positive tumor but not in the normal pancreatic tissue. When 34 used in combination with light treatment, it allowed delivery of selective photodynamic therapy (PDT) to 35 the cancerous tissues, with minimal harm to the adjacent normal tissues. With this novel Cath E activation 36 approach, it is possible to detect pancreatic cancer cells accurately and specifically impair their viability, 37 while sparing normal cells. This treatment could result in fewer side effects than the non-specific treatments 38 currently in use. Cath E is a specific and effective drug activator for PDAC treatment. 39 
Introduction
45
Pancreatic ductal adenocarcinoma (PDAC) remains a devastating 46 disease, with the worst outcome of all major cancers [1] . In the US, PDAC is the fourth leading cause of cancer death, with average survival vanced disease, in which a margin-negative resection is not feasible.
53
Unfortunately, no effective treatments for locally invasive and metastatic
54
PDAC are known at this time.
55
Currently, photodynamic therapy (PDT) is a widely accepted treat-56 ment modality for many cancerous and precancerous lesions, including 57 those in bladder, brain, ovary, and skin [3] [4] [5] . It is a minimally invasive light using a diode laser (652 nm) and incidence fluence rate of The 5-ALA prodrug was designed to release free 5-ALA upon selec-
219
tive Cath E cleavage of the scissile bond between Leu-and 5-ALA res-220 idues ( Supplementary Fig. 1A ). The biochemical selectivity of the 221 5-ALA prodrug was systematically tested using a panel of purified 222 proteolytic enzymes, i.e., Cath E, Cath D, and Cath B (50 pmol each).
223
The LC-MS results indicated that Cath E was the only tested protease Fig. 2A,B) . ing from cells treated with the 5-ALA prodrug (Fig. 1A, panel b) .
245
These signals were comparable to those obtained from cells treated
246
with the positive control, free 5-ALA (Fig. 1A, panel d) . To further con- suggested the lack of free 5-ALA within the cells (Fig. 1B, panel d) .
255
This result indicates that Cath E is required to release free 5-ALA
256
and initiate the subsequent synthesis of PpIX. ( Fig. 3A, right) , compared to those having limited Cath E expression,
281
MPanc96-FG30, (Fig. 3A, left) . As supported by the fluorescence images 282 (Fig. 1B) , the extent of cell damage corresponded to the level of Cath E 
were not seen in tissues treated with the 5-ALA prodrug. Therefore, endogenous Cath E, the 5-ALA residue was released and then used 
